Press releases
- CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
- Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
- Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
Key statistics
As of last trade CSL Ltd (CSJ:DUS) traded at 168.46, -12.49% below its 52-week high of 192.50, set on Jun 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 167.98 |
---|---|
High | 168.46 |
Low | 167.98 |
Bid | 168.22 |
Offer | 170.84 |
Previous close | 168.88 |
Average volume | 0.00 |
---|---|
Shares outstanding | 483.25m |
Free float | 481.01m |
P/E (TTM) | 35.47 |
Market cap | 133.28bn AUD |
EPS (TTM) | 7.78 AUD |
Annual div (ADY) | 2.36 EUR |
---|---|
Annual div yield (ADY) | 1.40% |
Div ex-date | Mar 11 2024 |
Div pay-date | Apr 03 2024 |
Data delayed at least 15 minutes, as of May 06 2024 15:30 BST.
More ▼